Table 3 Univariate analysis of clinical and physical dosimetric factors predicting the clinical outcomes of SARP

Clinical characteristics

Age (≤ 60 vs. > 60; years)

0.267

0.524

0.167–1.640

Gender (Male vs. Female)

0.274

3.643

0.359–36.986

ECOG PS (0–1 vs. 2)

0.068

3.243

0.867–3.653

COPD (Yes vs. No)

0.432

2.238

0.179–4.226

Smoking (< 20 vs. ≥ 20; pack year)

0.630

1.038

0.461–1.129

Diabetes (Yes vs. No)

0.095

0.153

0.017–1.390

Histology

SCC

0.997

Ref.

AC

0.963

1.029

0.331–3.407

Other

0.978

0.980

0.221–4.343

Ki-67 (≤ 20 vs. > 20; %)

0.477

1.422

0.538–3.758

Lobe

Left upper

0.736

Ref.

Left lower

0.594

0.681

0.165–2.804

Right middle

0.793

0.778

0.119–5.100

Right upper

0.159

0.259

0.040–1.700

Right lower

0.603

0.707

0.191–2.613

TNM stage (II vs. III)

0.729

0.729

0.246–2.663

Prior lung cancer surgery (Yes vs. No)

0.456

1.500

0.517–4.352

Chemotherapy (concurrent vs. sequential)

0.159

5.037

0.532–47.733

RT dose received

40 or 58 Gy

0.156

Ref.

59–60 Gy

0.310

2.500

0.426–14.657

61–65 Gy

0.075

4.750

0.854–26.432

Ipsilateral lung

V₅ (%)

0.014

0.972

0.951–0.994

V₁₀ (%)

0.099

0.977

0.951–1.004

V₁₅ (%)

0.407

0.987

0.956–1.018

V₂₀ (%)

0.501

1.011

0.978–1.046

V₃₀ (%)

0.014

1.046

1.009–1.084

Contralateral lung

V₅ (%)

0.004

0.951

0.919–0.984

V₁₀ (%)

0.037

0.953

0.911–0.997

V₁₅ (%)

0.189

0.967

0.920–1.017

V₂₀ (%)

0.925

0.998

0.950–1.047

V₃₀ (%)

0.034

1.053

1.004–1.105

Total lung

V₅ (%)

0.001

0.939

0.906–0.974

V₁₀ (%)

0.006

0.931

0.884–0.98

V₁₅ (%)

0.181

0.961

0906–1.019

V₂₀ (%)

0.261

1.033

0.976–1.093

V₃₀ (%)

0.003

1.104

1.035–1.178

MLD (cGy)

0.012

0.998

0.997–1.000

Heart mean dose (cGy)

0.023

1.001

1.000–1.001

Heart volume (cm³)

0.176

0.998

0.996–1.001

Maximum spinal cord dose (cGy)

0.004

1.001

1.000–1.001

PTV/LV

0.862

0.714

0.016–32.166

Segmentation model (routine segmentation/large segmentation)

0.798

1.167

0.358–3.801